Displaying drugs 11426 - 11450 of 11729 in total
T487
T487 is a small molecule chemokine receptor antagonist to correct or modify immune system responses. It binds selectively and potently to CXCR3. The formulation is administered orally and has anti-inflammatory effects in conditions such as rheumatoid arthritis, inflammatory bowel disease and psoriasis.
Investigational
Matched Description: … T487 is a small molecule chemokine receptor antagonist to correct or modify immune system responses. …
Delgocitinib
Delgocitinib is under investigation in clinical trial NCT03683719 (Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 Mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema).
Investigational
Matched Description: … Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 Mg/g Compared to Delgocitinib Cream Vehicle Over a …
D2C7 immunotoxin
D2C7 immunotoxin (D2C7-IT) is an investigational dual-specific monoclonal antibody targeting EGFRwt and EGFRvIII with a genetically engineered form of the Pseudomonas exotoxin, PE38-KDEL. D2C7-IT is under investigation in clinical trial NCT04160494 (D2C7-IT With Atezolizumab for Recurrent Gliomas).
Investigational
Matched Description: … D2C7-IT) is an investigational dual-specific monoclonal antibody targeting EGFRwt and EGFRvIII with a …
RGX-501
RGX-501 is an adeno-associated virus vector 8 (AAV8)-mediated gene therapy that delivers a functional copy of the human low-density lipoprotein receptor (LDLR) gene to liver cells. It is being investigated for the treatment of homozygous familial hypercholesterolemia.
Investigational
Matched Description: … RGX-501 is an adeno-associated virus vector 8 (AAV8)-mediated gene therapy that delivers a functional …
PS386113
PS386113 is a small molecule drug candidate under investigation for the treatment of inflammatory disorders. It is being developed by Schering-Plough and Pharmacopeia. Little information has been released about PS386113.
Investigational
Matched Description: … PS386113 is a small molecule drug candidate under investigation for the treatment of inflammatory disorders …
(R)-Fluoxetine
An N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine that has R configuration (the antidepressant drug fluoxetine is a racemate comprising equimolar amounts of (R)- and (S)-fluoxetine).
Experimental
Matched Description: … trifluoromethyl)phenoxy]propan-1-amine that has R configuration (the antidepressant drug fluoxetine is a …
Deleobuvir
Deleobuvir is under investigation in clinical trial NCT01983566 (Effect of Food and Increased Gastric pH Value on Bioavailability of a Single Dose of BI 207127 in Healthy Caucasian and Japanese Subjects).
Investigational
Matched Description: … in clinical trial NCT01983566 (Effect of Food and Increased Gastric pH Value on Bioavailability of a …
Fulacimstat
Fulacimstat is under investigation in clinical trial NCT02452515 (A Single-blind Pilot Study to Investigate Safety and Tolerability of the Chymase Inhibitor BAY1142524 in Clinically Stable Patients With Left-ventricular Dysfunction).
Investigational
Matched Description: … Fulacimstat is under investigation in clinical trial NCT02452515 (A Single-blind Pilot Study to Investigate …
MK-2748
MK-2748 is under investigation in clinical trial NCT01593735 (A Multiple Dose Study to Evaluate the Safety and Efficacy of MK-2748 in Hepatitis C-Infected Participants (MK-2748-002 AM1)).
Investigational
Matched Description: … MK-2748 is under investigation in clinical trial NCT01593735 (A Multiple Dose Study to Evaluate the Safety …
Ilacirnon
Ilacirnon (CCX-140) is under investigation in clinical trial NCT01440257 (A Study to Evaluate the Effect of CCX140-B on Urinary Albumin Excretion in Subjects With Type 2 Diabetes and Albuminuria).
Investigational
Matched Description: … Ilacirnon (CCX-140) is under investigation in clinical trial NCT01440257 (A Study to Evaluate the Effect …
Tiragolumab
Tiragolumab is under investigation in clinical trial NCT04513925 (A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)).
Investigational
Matched Description: … Tiragolumab is under investigation in clinical trial NCT04513925 (A Study of Atezolizumab and Tiragolumab …
BBM-H901
BBM-H901 is a liver-tropic adeno-associated viral (AAV) vector carrying cassette coding hyperactive Padua factor IX (FIX) protein. It is being investigated for the treatment of hemophilia B.
Investigational
Matched Description: … BBM-H901 is a liver-tropic adeno-associated viral (AAV) vector carrying cassette coding hyperactive Padua …
LX6171
LX6171 is an oral drug candidate that was generated by Lexicon medicinal chemists and is being developed to treat disorders characterized by cognitive impairment, such as Alzheimer's disease, schizophrenia or vascular dementia.
Investigational
Puromycin
Puromycin is an antibiotic that prevents bacterial protein translation. It is utilized as a selective agent in laboratory cell cultures. Puromycin is toxic to both prokaryotic and eukaryotic cells, resulting in significant cell death at appropriate doses.
Experimental
Matched Description: … It is utilized as a selective agent in laboratory cell cultures. …
Theralizumab
Theralizumab is a humanized anti-CD28 monoclonal antibody designed for treating autoimmune diseases and cancer. After the first human trial, it was withdrawn due to severe toxicity (likely due to lymphopenia and human cytokine release).[A216527,A216532]
Investigational
Matched Description: … Theralizumab is a humanized anti-CD28 monoclonal antibody designed for treating autoimmune diseases and …
Velsecorat
Velsecorat is under investigation in clinical trial NCT02479412 (A Multiple Dosing (14 Days) Study to Assess Efficacy and Safety of Three Dose Levels of AZD7594, Given Once Daily by Inhalation, in Patients With Mild to Moderate Asthma).
Investigational
Matched Description: … Velsecorat is under investigation in clinical trial NCT02479412 (A Multiple Dosing (14 Days) Study to …
MF101
MF101 is a novel estrogen receptor beta (ERβ) selective agonist and unlike currently available hormone therapies, does not activate the estrogen receptor alpha (ERα), known to be implicated in tumor formation. MF101 is an oral drug designed for the treatment of hot flashes and night sweats in peri-menopausal and menopausal...
Investigational
Matched Description: … MF101 is a novel estrogen receptor beta (ERβ) selective agonist and unlike currently available hormone …
Tasosartan
Tasosartan is a long-acting angiotensin II (AngII) receptor blocker. Its long duration of action has been attributed to its active metabolite enoltasosartan. It is used to treat patients with essential hypertension.
Experimental
Matched Description: … Tasosartan is a long-acting angiotensin II (AngII) receptor blocker. …
CVT-6883
CVT-6883 is a selective, potent and orally available A2B-adenosine receptor antagonist which CV Therapeutics is investigating for the potential treatment of asthma and other conditions related to inflammation and fibrosis.
Investigational
Matched Description: … CVT-6883 is a selective, potent and orally available A2B-adenosine receptor antagonist which CV Therapeutics …
Molibresib
Molibresib is under investigation in clinical trial NCT01943851 (A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies).
Investigational
Matched Description: … Molibresib is under investigation in clinical trial NCT01943851 (A Dose Escalation Study to Investigate …
Lobeline
An alkaloid that has actions similar to nicotine on nicotinic cholinergic receptors but is less potent. It has been proposed for a variety of therapeutic uses including in respiratory disorders, peripheral vascular disorders, insomnia, and smoking cessation. [PubChem]
Investigational
Matched Description: … It has been proposed for a variety of therapeutic uses including in respiratory disorders, peripheral …
D-JNKI-1
A synthetic, cell permeable peptide that blocks the MAPK-JNK signal pathway; has potential therapeutic value for long-term protection of both the morphological integrity and physiological function of the organ of Corti during times of oxidative stress.
Investigational
Matched Description: … A synthetic, cell permeable peptide that blocks the MAPK-JNK signal pathway; has potential therapeutic …
PI-166
PI-166 is a small organic compound with specific avidity to liver cancer cells. It has demonstrated the ability to reduce the growth of rat hepatomas, which is like human hepatomas, are resistant to established anti-cancer agents.
Investigational
Matched Description: … PI-166 is a small organic compound with specific avidity to liver cancer cells. …
PF-05241328
PF-05241328 is under investigation in clinical trial NCT01165736 (To Calculate the Pharmacokinetics (Concentration of Compound in and Rate of Excretion From the Blood) Following a Very Low Dose of Compound Which Will Not Have Any Pharmacological Activity).
Investigational
Matched Description: … the Pharmacokinetics (Concentration of Compound in and Rate of Excretion From the Blood) Following a …
Displaying drugs 11426 - 11450 of 11729 in total